Home » Stocks » ADRO

Aduro BioTech, Inc. (ADRO)

Oct 6, 2020 - ADRO merged into KDNY
Stock Price: $14.60 USD 0.00 (0.00%)
Updated Oct 5, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 237.01M
Revenue (ttm) 27.96M
Net Income (ttm) -64.56M
Shares Out 16.23M
EPS (ttm) -4.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 5, 2020
Last Price $14.60
Previous Close $14.60
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 13.92 - 14.86
Day's Volume 0
52-Week Range 4.51 - 20.20

More Stats

Market Cap 237.01M
Enterprise Value 98.01M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 16.23M
Float n/a
EPS (basic) -4.00
EPS (diluted) -4.01
FCF / Share -4.15
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.21M
Short Ratio 4.66
Short % of Float n/a
Beta 0.39
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.48
PB Ratio 4.23
Revenue 27.96M
Operating Income -76.26M
Net Income -64.56M
Free Cash Flow -67.09M
Net Cash 139.00M
Net Cash / Share 8.56
Gross Margin -173.88%
Operating Margin -272.79%
Profit Margin -230.90%
FCF Margin -239.98%
ROA -13.90%
ROE -87.44%
ROIC -38.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 1
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$18.75*
Low
18.8
Current: $14.60
High
18.8
Target: 18.75
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue17.2615.0917.2450.6872.9813.390.83
Revenue Growth14.39%-12.48%-65.99%-30.55%445.07%1517.03%-
Gross Profit17.2615.0917.2450.6872.9813.390.83
Operating Income-90.14-101-106-71.86-13.56-19.12-14.54
Net Income-82.37-95.36-91.86-91.15-39.21-17.01-16.05
Shares Outstanding80.1178.8172.9065.2044.710.320.29
Earnings Per Share-1.03-1.21-1.26-1.40-0.88-53.06-55.80
Operating Cash Flow-65.51-68.76-88.86-86.0815519.37-14.23
Capital Expenditures-1.26-2.32-5.15-23.89-2.17-0.78-0.17
Free Cash Flow-66.77-71.08-94.01-11015318.58-14.40
Cash & Equivalents2142673273484161198.53
Total Debt33.44-----12.99
Net Cash / Debt181267327348416119-4.46
Assets2913584454394821269.88
Liabilities22622220821122047.8016.41
Book Value65.60135237227262-61.30-38.76
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aduro BioTech, Inc.
Country United States
Employees 69
CEO Stephen T. Isaacs

Stock Information

Ticker Symbol ADRO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ADRO
IPO Date April 15, 2015

Description

Aduro Biotech, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; and license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro Biotech, Inc. in June 2008. Aduro Biotech, Inc. was founded in 2000 and is headquartered in Berkeley, California.